Consensus Predictive Model for Human K562 Cell Growth Inhibition through Enalos Cloud Platform

β‐Thalassemia is an inherited hematologic disorder caused by various mutations of the β‐globin gene, thus resulting in a significant decrease in adult hemoglobin (HbA) production. An increase in fetal hemoglobin (HbF) levels by drug molecules is considered of great potential in β‐thalassemia treatment and is expected to counterbalance the impaired production of HbA. In this work, based on a set of 129 experimentally tested biological inhibitors, we developed and validated a computational model for the prediction of K562 functional inhibition, possibly associated with HbF induction. To facilitate future advancements in the field, we incorporated our model into Enalos Cloud Platform, which enabled online access to our computational scheme (http://enalos.insilicotox.com/K562) through a user‐friendly interface. This web service is offered to the wider community to promote in silico drug discovery through fast and reliable predictions.

[1]  Chi Ma,et al.  Induction of human fetal hemoglobin expression by adenosine-2’,3’-dialdehyde , 2013, Journal of Translational Medicine.

[2]  Roberto Gambari,et al.  Resveratrol: Antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patients. , 2012, International journal of molecular medicine.

[3]  Igor V. Tetko,et al.  The perspectives of computational chemistry modeling , 2011, Journal of Computer-Aided Molecular Design.

[4]  Georgia Melagraki,et al.  Editorial: Towards Open Access for Cheminformatics. , 2016, Combinatorial chemistry & high throughput screening.

[5]  Alexander Tropsha,et al.  Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.

[6]  J. L. Delgado-Lamas,et al.  Thalidomide therapy in a patient with thalassemia major. , 2008, Blood cells, molecules & diseases.

[7]  Ming Liu,et al.  Human fetal globin gene expression is regulated by LYAR , 2014, Nucleic acids research.

[8]  George Kollias,et al.  Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL) , 2017, PLoS Comput. Biol..

[9]  Dvorit Samid,et al.  Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. , 1992 .

[10]  G. Melagraki,et al.  Enalos KNIME nodes: Exploring corrosion inhibition of steel in acidic medium , 2013 .

[11]  R. Todeschini,et al.  Molecular Descriptors for Chemoinformatics: Volume I: Alphabetical Listing / Volume II: Appendices, References , 2009 .

[12]  Y. Zhao,et al.  Comparison of decision tree methods for finding active objects , 2007, 0708.4274.

[13]  L. Blanc,et al.  Blood Cells , Molecules , and Diseases , 2017 .

[14]  Daniele Simoni,et al.  Effects of Pimozide Derivatives on pSTAT5 in K562 Cells , 2017, ChemMedChem.

[15]  E. Vichinsky,et al.  Darbepoetin alfa for the treatment of anaemia in alpha‐ or beta‐ thalassaemia intermedia syndromes , 2011, British journal of haematology.

[16]  Antonio Monge,et al.  Ester of Quinoxaline-7-carboxylate 1,4-di-N-oxide as Apoptosis Inductors in K-562 Cell Line: An in vitro, QSAR and DFT Study. , 2017, Anti-cancer agents in medicinal chemistry.

[17]  Linden J Gearing,et al.  Transcriptional regulators Myb and BCL11A interplay with DNA methyltransferase 1 in developmental silencing of embryonic and fetal β‐like globin genes , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  T. Townes,et al.  KLF1 regulates BCL11A expression and γ- to β-globin gene switching , 2010, Nature Genetics.

[19]  Yukio Nakamura,et al.  Induction of adult levels of β-globin in human erythroid cells that intrinsically express embryonic or fetal globin by transduction with KLF1 and BCL11A-XL , 2014, Haematologica.

[20]  Georgia Melagraki,et al.  Enalos InSilicoNano platform: an online decision support tool for the design and virtual screening of nanoparticles , 2014 .

[21]  Chad Garner,et al.  Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. , 2009, Human molecular genetics.

[22]  S. Mane,et al.  Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2. , 2002, Blood.

[23]  Roberto Gambari,et al.  Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. , 2007, Current medicinal chemistry.

[24]  G. Atweh,et al.  Pharmacologic induction of fetal hemoglobin production. , 2010, Hematology/oncology clinics of North America.

[25]  J. T. Jayne,et al.  6 7 8 , 2003 .

[26]  S. Sheth,et al.  Red blood cell transfusions for thalassemia: results of a survey assessing current practice and proposal of evidence‐based guidelines , 2014, Transfusion.

[27]  Giannis Tzimas,et al.  Updates of the HbVar database of human hemoglobin variants and thalassemia mutations , 2013, Nucleic Acids Res..

[28]  Alexander Golbraikh,et al.  A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR Models , 2006, J. Chem. Inf. Model..

[29]  Georgia Melagraki,et al.  Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors. , 2017, Mini reviews in medicinal chemistry.

[30]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[31]  Hyunsu Bae,et al.  Evidence Based Complementary and Alternative Medicine , 2008, Evidence-based complementary and alternative medicine : eCAM.

[32]  D. J. Weatherall,et al.  4 Pathophysiology of thalassaemia , 1998 .

[33]  Jennifer G Michlitsch,et al.  Recent advances in bone marrow transplantation in hemoglobinopathies. , 2008, Current molecular medicine.

[34]  Kunal Roy,et al.  Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection , 2011 .

[35]  J. Clegg,et al.  K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin , 1979, Nature.

[36]  Khaled M Musallam,et al.  Optimal management of β thalassaemia intermedia , 2011, British journal of haematology.

[37]  Anita Nadkarni,et al.  Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders , 2010, Expert review of hematology.

[38]  Paola Gramatica,et al.  Development, Validation and Inspection of the Applicability Domain of QSPR Models for Physicochemical Properties of Polybrominated Diphenyl Ethers , 2009 .

[39]  George Kollias,et al.  Ligand-based virtual screening procedure for the prediction and the identification of novel β-amyloid aggregation inhibitors using Kohonen maps and Counterpropagation Artificial Neural Networks. , 2011, European journal of medicinal chemistry.

[40]  C. Lowrey,et al.  Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. , 2011, Blood.

[41]  R. W. Jones,et al.  Embryonic erythroid differentiation in the human leukemic cell line K562. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Amal El-Beshlawy,et al.  Fetal Globin Induction in β-thalassemia , 2009, Hemoglobin.

[43]  Paola Gramatica,et al.  The applications of machine learning algorithms in the modeling of estrogen-like chemicals. , 2009, Combinatorial chemistry & high throughput screening.

[44]  Ping Yi,et al.  3D QSAR Studies on Cytotoxicity of Ent-Kauranoids against K562 Cells by CoMFA , 2012 .

[45]  B. Pace,et al.  Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. , 2014, Hematology/oncology clinics of North America.

[46]  Roberto Gambari,et al.  Recent trends for novel options in experimental biological therapy of β-thalassemia , 2014, Expert opinion on biological therapy.

[47]  Wei Li,et al.  Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line , 2010, Experimental biology and medicine.

[48]  Roberto Gambari,et al.  Alternative options for DNA-based experimental therapy of β-thalassemia , 2012, Expert opinion on biological therapy.

[49]  Roberto Gambari,et al.  Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin , 2015, Experimental hematology.

[50]  D. Samid,et al.  Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. , 1992, The New England journal of medicine.

[51]  Stuart H. Orkin,et al.  Developmental and species-divergent globin switching are driven by BCL11A , 2009, Nature.

[52]  R. Calzolari,et al.  Desensitization to hydroxycarbamide following long‐term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients , 2010, British journal of haematology.

[53]  Steve Best,et al.  cMYB is involved in the regulation of fetal hemoglobin production in adults. , 2006, Blood.

[54]  J. Georgiou,et al.  Administration of high doses of recombinant human erythropoietin to patients with β‐thalassemia intermedia: a preliminary trial , 1997, European journal of haematology.

[55]  S. L. Khokra,et al.  Pharmacophore modeling studies on N-hydroxyphenyl acrylamides and N-hydroxypyridin-2-yl-acrylamides as inhibitor of human cancer leukemia K562 cells , 2013, Medicinal Chemistry Research.

[56]  A. Schechter,et al.  Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. , 1993, The New England journal of medicine.

[57]  Emilio Benfenati,et al.  The application of new HARD-descriptor available from the CORAL software to building up NOAEL models. , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[58]  D J Weatherall,et al.  The therapeutic reactivation of fetal haemoglobin. , 1998, Human molecular genetics.

[59]  Peter Ertl,et al.  JSME: a free molecule editor in JavaScript , 2013, Journal of Cheminformatics.

[60]  Cong Peng,et al.  Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing , 2011, Science.

[61]  Swee Lay Thein,et al.  The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. , 2012, Blood reviews.

[62]  Kunal Roy,et al.  Development of a robust and validated 2D-QSPR model for sweetness potency of diverse functional organic molecules. , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[63]  Swee Lay Thein,et al.  Molecular therapies in β‐thalassaemia , 2007, British journal of haematology.

[64]  E. Reddy,et al.  Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. , 2010, Bioorganic & medicinal chemistry.

[65]  G. Stamatoyannopoulos,et al.  Butyrate increases the efficiency of translation of γ-globin mRNA , 2005 .

[66]  Roberto Gambari,et al.  Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of β-Thalassemia and Sickle-Cell Anemia , 2007, Evidence-based complementary and alternative medicine : eCAM.

[67]  Gennady Verkhivker,et al.  Design, Synthesis, and Evaluation of Dasatinib–Amino Acid and Dasatinib–Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors , 2016, ChemMedChem.

[68]  Philip D. Gregory,et al.  Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping , 2014, Cell.

[69]  G. Melagraki,et al.  A Risk Assessment Tool for the Virtual Screening of Metal Oxide Nanoparticles through Enalos InSilicoNano Platform. , 2015, Current topics in medicinal chemistry.

[70]  Ian H. Witten,et al.  The WEKA data mining software: an update , 2009, SKDD.

[71]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[72]  George Kollias,et al.  Molecular Modeling on Pyrimidine-Urea Inhibitors of TNF-α Production: An Integrated Approach Using a Combination of Molecular Docking, Classification Techniques, and 3D-QSAR CoMSIA , 2012, J. Chem. Inf. Model..

[73]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .

[74]  Pascal Sonnet,et al.  Synthesis and Antiproliferative Effect of Ethyl 4‐[4‐(4‐Substituted Piperidin‐1‐yl)]benzylpyrrolo[1,2‐a]quinoxalinecarboxylate Derivatives on Human Leukemia Cells , 2017, ChemMedChem.

[75]  Matthew C. Canver,et al.  miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  D. J. Weatherall,et al.  Phenotype—genotype relationships in monogenic disease: lessons from the thalassaemias , 2001, Nature Reviews Genetics.

[77]  Haralambos Sarimveis,et al.  A Novel QSAR Model for Evaluating and Predicting the Inhibition Activity of Dipeptidyl Aspartyl Fluoromethylketones , 2006 .

[78]  Paul Hofman,et al.  Imatinib induces mitochondria‐dependent apoptosis of the Bcr‐Abl‐positive K562 cell line and its differentiation toward the erythroid lineage 1 , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  Roberto Todeschini,et al.  Molecular descriptors for chemoinformatics , 2009 .

[80]  Xiaoxin Xu,et al.  Induction of endogenous γ-globin gene expression with decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence , 2009, Journal of hematology & oncology.

[81]  Stuart H. Orkin,et al.  Hematopoietic SIN Lentiviral Micro RNA-Mediated Silencing of BCL11A: Pre-Clinical Evidence for a Sickle Cell Disease Gene-Therapy Trial , 2012 .

[82]  J. Old,et al.  Screening and genetic diagnosis of haemoglobin disorders. , 2003, Blood reviews.

[83]  O. Witt,et al.  Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. , 2003, Blood.

[84]  Roberto Gambari,et al.  Effects of rapamycin on accumulation of α‐, β‐ and γ‐globin mRNAs in erythroid precursor cells from β‐thalassaemia patients , 2006 .

[85]  J. Hirschhorn,et al.  Supporting Online Material Materials and Methods Figs. S1 to S10 Tables S1 to S7 References Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-specific Repressor Bcl11a , 2022 .

[86]  T. Martin,et al.  Anti-Cancer agents in medicinal chemistry (Formerly current medicinal chemistry - Anti-cancer agents). , 2010, Anti-cancer agents in medicinal chemistry.

[87]  Weida Tong,et al.  Mold2, Molecular Descriptors from 2D Structures for Chemoinformatics and Toxicoinformatics , 2008, J. Chem. Inf. Model..